We were interested in exploring the efficacy and safety of varenicline as an adjunct to a healthy lifestyle intervention for smoking cessation among individuals with a severe mental illness.
Methods
We used varenicline as an adjunct to a healthy lifestyle intervention in 14 smokers with a psychotic illness.
Results
Overall, smoking cessation rates were 36% at 3 months and 42% at 6 months. The most commonly reported side effects were sleep disturbance and nausea. These tended to occur early in treatment, and patients responded to general measures of support and reassurance. Of the 14 participants, 1 dropped out because of psychiatric problems and 2 because of other side effects.
Conclusions
Varenicline appears to be an effective adjunct to a healthy lifestyle intervention for smokers with a psychotic illness. Although the results of this open study are encouraging, replication in an adequately powered, randomized controlled trial is required before definitive conclusions can be drawn.
JablenskyA, McGrathJ, HerrmanH, . Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Aust N Z J Psychiatry. 2000;34:221–236.
2.
KellyDL, McMahonRP, WehringHJ, . Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull. 2011;37:832–838.
3.
BakerA, IversRG, BowmanJ, . Where there's smoke, there's fire: high prevalence of smoking among some sub-populations and recommendations for intervention. Drug Alcohol Rev. 2006;25:85–96.
4.
El-GuebalyN, CathcartJ, CurrieS, . Smoking cessation approaches for persons with mental illness or addictive disorders. Psychiatr Serv. 2002;53:1166–1170.
5.
AddingtonJ, el-GuebalyN, CampbellW, . Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry. 1998;155:974–976.
6.
ZiedonisDM, GeorgeTP.Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull. 1997;23:247–254.
7.
GeorgeTP, ZiedonisDM, FeingoldA, . Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157:1835–1842.
8.
EvinsAE, MaysVK, RigottiNA, . A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res. 2001;3:397–403.
9.
GeorgeTP, VessicchioJC, TermineA, . A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002;52:53–61.
10.
EvinsAE, CatherC, CulhaneMA, . A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27:380–386.
11.
EvinsAE, CatherC, DeckersbachT, . A doubleblind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25:218–225.
12.
GeorgeTP, VessicchioJC, SaccoKA, . A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2008;63:1092–1096.
13.
BakerA, RichmondR, HaileM, . A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry. 2006;163:1934–1942.
14.
BakerA, RichmondR, HaileM, . Characteristics of smokers with a psychotic disorder and implications for smoking interventions. Psychiatry Res. 2007;150:141–152.
15.
BakerA, RichmondR, CastleD, . Coronary heart disease risk reduction intervention among overweight smokers with a psychotic disorder: pilot trial. Aust N Z J Psychiatry. 2009;43:129–135.
16.
BakerA, Kay-LambkinFJ, RichmondR, . Study protocol: a randomised controlled trial investigating the effect of a healthy lifestyle intervention for people with severe mental disorders. BMC Public Health. 2011;11:10.
17.
GonzalesD, RennardSI, NidesM, . Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47–55.
18.
JorenbyDE, HaysJT, RigottiNA, . Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.
19.
NidesM, OnckenC, GonzalesD, . Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166:1561–1568.
20.
TonstadS, TønnesenP, HajekP, . Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64–71.
21.
WilliamsKE, ReevesKR, BillingCBJr, . A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007;23:793–801.
22.
KuehnBM.FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA. 2008;299:1121–1122.
23.
GunnellD, IrvineD, WiseL, . Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805.
24.
FreedmanR.Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007;164:1269.
25.
KohenI, KremenN.Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007;164:1269–1270.
26.
LecrubierY, SheehanDV, WeillerE, . The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry. 1997;12:224–231.
27.
DarkeS, HallW, WodakA, . Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict. 1992;87:733–742.
28.
HeathertonTF, KozlowskiLT, FreckerRC, . The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86:1119–1127.
29.
HughesJR, HatsukamiD.Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43:289–294.
30.
VenturaJ, LukoffD, NuechterleinKH, . Brief Psychiatric Rating Scale. Expanded version (4.0). Scales, anchor points, and administration manual. Int J Methods Psychiatr Res. 1993;3:227–243.
YoungRC, BiggsJT, ZieglerVE, . A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435.
33.
StapletonJA, WatsonL, SpirlingLI, . Varenicline in the routine treatment of tobacco dependence: a prepost comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103:146–154.
34.
PurvisTL, MambourgSE, BalvanzTM, . Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. Ann Pharmacother. 2009;43:862–867.
35.
McClureJB, SwanGE, JackL, . Mood, sideeffects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med. 2009;24:563–569.
36.
SmithRC, LindenmayerJP, DavisJM, . Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2009;110:149–155.
37.
WeinerE, BuchholzA, CoffayA, . Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res. 2011;129:94–95.
38.
CoveyLS, GlassmanAH, StetnerF.Major depression following smoking cessation. Am J Psychiatry. 1997;154:263–265.
39.
HongLE, ThakerGK, McMahonRP, . Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 2011;68:1195–1206.
